Display options
Cite
Hwang YC, Jun JE, Jeong IK, et al. Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus. Diabetes Metab J. 2019;43(5):582-589doi: 10.4093/dmj.2018.0124.
Hwang, Y. C., Jun, J. E., Jeong, I. K., Ahn, K. J., & Chung, H. Y. (2019). Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus. Diabetes & metabolism journal, 43(5), 582-589. https://doi.org/10.4093/dmj.2018.0124
Hwang, You Cheol, et al. "Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus." Diabetes & metabolism journal vol. 43,5 (2019): 582-589. doi: https://doi.org/10.4093/dmj.2018.0124
Hwang YC, Jun JE, Jeong IK, Ahn KJ, Chung HY. Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus. Diabetes Metab J. 2019 Oct;43(5):582-589. doi: 10.4093/dmj.2018.0124. Epub 2019 Jan 16. PMID: 30688048; PMCID: PMC6834829.
Copy Download .nbib Format: NLM
Share it on

Diabetes Metab J. 2019 Oct;43(5):582-589. doi: 10.4093/dmj.2018.0124. Epub 2019 Jan 16.

Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus.

Diabetes & metabolism journal

You Cheol Hwang, Ji Eun Jun, In Kyung Jeong, Kyu Jeung Ahn, Ho Yeon Chung

Affiliations

  1. Division of Endocrinology and Metabolism, Department of Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea. [email protected].
  2. Division of Endocrinology and Metabolism, Department of Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea.

PMID: 30688048 PMCID: PMC6834829 DOI: 10.4093/dmj.2018.0124

Abstract

BACKGROUND: The apolipoprotein B/A1 (apoB/A1) ratio is a stronger predictor of future cardiovascular disease than is the level of conventional lipids. Statin and ezetimibe combination therapy have shown additional cardioprotective effects over statin monotherapy.

METHODS: This was a single-center, randomized, open-label, active-controlled study in Korea. A total of 36 patients with type 2 diabetes mellitus were randomized to either rosuvastatin monotherapy (20 mg/day,

RESULTS: After the 6-week treatment, low density lipoprotein cholesterol (LDL-C) and apoB reduction were comparable between the two groups (-94.3±15.4 and -62.0±20.9 mg/dL in the rosuvastatin group, -89.9±22.7 and -66.8±21.6 mg/dL in the rosuvastatin/ezetimibe group,

CONCLUSION: A 6-week combination therapy of low-dose rosuvastatin and ezetimibe showed LDL-C, apoB, and apoB/A1 ratio reduction comparable to that of high-dose rosuvastatin monotherapy in patients with type 2 diabetes mellitus. Triglyceride and FFA reductions were greater with the combination therapy than with rosuvastatin monotherapy.

Copyright © 2019 Korean Diabetes Association.

Keywords: Apolipoprotein A-I; Apolipoproteins B; Ezetimibe; Fatty acids, nonesterified; Rosuvastatin calcium; Triglycerides

Conflict of interest statement

This study was financially supported by Daewoong Pharmaceutical Co, Ltd, Seoul, Korea.

References

  1. J Clin Lipidol. 2016 Mar-Apr;10(2):306-13 - PubMed
  2. Am J Cardiovasc Drugs. 2008;8(6):373-418 - PubMed
  3. Cardiovasc Ther. 2014 Apr;32(2):40-6 - PubMed
  4. J Am Coll Cardiol. 2016 May 24;67(20):2395-2410 - PubMed
  5. J Intern Med. 2006 May;259(5):493-519 - PubMed
  6. Circ Heart Fail. 2013 Sep 1;6(5):964-9 - PubMed
  7. J Intern Med. 2006 May;259(5):437-46 - PubMed
  8. Br J Clin Pharmacol. 2016 May;81(5):807-18 - PubMed
  9. Circulation. 2002 Oct 8;106(15):1943-8 - PubMed
  10. N Engl J Med. 2015 Jun 18;372(25):2387-97 - PubMed
  11. Lipids Health Dis. 2015 Apr 23;14:37 - PubMed
  12. Stroke. 2013 Jul;44(7):1833-9 - PubMed
  13. Pharmacol Rep. 2014 Jun;66(3):442-7 - PubMed
  14. J Cardiovasc Pharmacol Ther. 2010 Jun;15(2):167-74 - PubMed
  15. Clin Ther. 2017 Jan;39(1):107-117 - PubMed
  16. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934 - PubMed
  17. J Intern Med. 2009 May;265(5):568-80 - PubMed
  18. Circulation. 2003 May 20;107(19):2409-15 - PubMed
  19. J Clin Endocrinol Metab. 2006 Jul;91(7):2542-7 - PubMed
  20. BMJ. 2014 May 29;348:g3244 - PubMed
  21. Lancet. 2003 Mar 1;361(9359):777-80 - PubMed
  22. Diabetologia. 1985 Jul;28(7):412-9 - PubMed
  23. Cardiovasc Ther. 2016 Oct;34(5):371-82 - PubMed
  24. Clin Chem Lab Med. 2008;46(4):429-34 - PubMed

Publication Types

Grant support